161 related articles for article (PubMed ID: 29473311)
1. HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1.
Kumagai T; Tomita Y; Nakatsuka SI; Kimura M; Kunimasa K; Inoue T; Tamiya M; Nishino K; Susaki Y; Kusu T; Tokunaga T; Okami J; Higashiyama M; Imamura F
Thorac Cancer; 2018 Apr; 9(4):466-471. PubMed ID: 29473311
[TBL] [Abstract][Full Text] [Related]
2. Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma.
Elebro J; Heby M; Warfvinge CF; Nodin B; Eberhard J; Jirström K
PLoS One; 2016; 11(4):e0153533. PubMed ID: 27070783
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and therapeutic ERβ, HER2, BRCA biomakers in the histological subtypes of lung adenocarcinoma according to the IASLC/ATS/ERS classification.
Zhong L; Zhang C; Jia W; Zhang P
Ann Diagn Pathol; 2021 Apr; 51():151700. PubMed ID: 33465722
[TBL] [Abstract][Full Text] [Related]
4. EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma.
Chen HY; Liu CH; Chang YH; Yu SL; Ho BC; Hsu CP; Yang TY; Chen KC; Hsu KH; Tseng JS; Hsia JY; Chuang CY; Chang CS; Li YC; Li KC; Chang GC; Yang PC
Oncotarget; 2016 Feb; 7(8):9017-25. PubMed ID: 26824984
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
[TBL] [Abstract][Full Text] [Related]
6. Distinctive clinicopathological features of adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung: A retrospective study.
Ishida H; Shimizu Y; Sakaguchi H; Nitanda H; Kaneko K; Yamazaki N; Yanagihara A; Taguchi R; Sakai F; Yasuda M; Kobayashi K
Lung Cancer; 2019 Mar; 129():16-21. PubMed ID: 30797486
[TBL] [Abstract][Full Text] [Related]
7. Computed tomography characteristics of lung adenocarcinomas with epidermal growth factor receptor mutation: A propensity score matching study.
Suh YJ; Lee HJ; Kim YJ; Kim KG; Kim H; Jeon YK; Kim YT
Lung Cancer; 2018 Sep; 123():52-59. PubMed ID: 30089595
[TBL] [Abstract][Full Text] [Related]
8. Lung Adenocarcinoma With MUC4 Expression Is Associated With Smoking Status, HER2 Protein Expression, and Poor Prognosis: Clinicopathologic Analysis of 338 Cases.
Rokutan-Kurata M; Yoshizawa A; Sumiyoshi S; Sonobe M; Menju T; Momose M; Koyama M; Shigeto S; Fujimoto M; Zhang M; Morita S; Date H; Haga H
Clin Lung Cancer; 2017 Jul; 18(4):e273-e281. PubMed ID: 28065467
[TBL] [Abstract][Full Text] [Related]
9. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
Willmore-Payne C; Holden JA; Layfield LJ
Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
[TBL] [Abstract][Full Text] [Related]
10. Molecular biological analysis in a patient with multiple lung adenocarcinomas.
Wakayama T; Hirata H; Suka S; Sato K; Tatewaki M; Souma R; Satoh H; Tamura M; Matsumura Y; Imada H; Sugiyama K; Arima M; Kurasawa K; Fukuda T; Fukushima Y
Thorac Cancer; 2018 May; 9(5):662-665. PubMed ID: 29577613
[TBL] [Abstract][Full Text] [Related]
11. Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung.
Awaya H; Takeshima Y; Furonaka O; Kohno N; Inai K
J Clin Pathol; 2005 Oct; 58(10):1076-80. PubMed ID: 16189154
[TBL] [Abstract][Full Text] [Related]
12. Afatinib as first-line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature.
Shi Y; Wang M
Thorac Cancer; 2018 Dec; 9(12):1788-1794. PubMed ID: 30379401
[TBL] [Abstract][Full Text] [Related]
13. CT texture analysis of lung adenocarcinoma: can Radiomic features be surrogate biomarkers for EGFR mutation statuses.
Mei D; Luo Y; Wang Y; Gong J
Cancer Imaging; 2018 Dec; 18(1):52. PubMed ID: 30547844
[TBL] [Abstract][Full Text] [Related]
14. Impact of HER2 codon 655 polymorphism and expression of HER2 and HER3 in non small cell lung cancer patients.
Ananiev J; Aleksandrova E; Skerleva D; Gulubova M; Chokoeva A; Lotti T; Wollina U; Tchernev G; Kontić M; Stojšić J
Wien Med Wochenschr; 2015 Aug; 165(15-16):315-21. PubMed ID: 26208475
[TBL] [Abstract][Full Text] [Related]
15. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains.
Li C; Sun Y; Fang R; Han X; Luo X; Wang R; Pan Y; Hu H; Zhang Y; Pao W; Shen L; Ji H; Chen H
J Thorac Oncol; 2012 Jan; 7(1):85-9. PubMed ID: 22071781
[TBL] [Abstract][Full Text] [Related]
16. Radiopathologic correlation of collision lung cancer with ground-glass opacity.
Uchida S; Tsuta K; Kusumoto M; Shiraishi K; Kohno T; Watanabe SI
Asian Cardiovasc Thorac Ann; 2019 Jan; 27(1):45-48. PubMed ID: 30417682
[TBL] [Abstract][Full Text] [Related]
17. Assessment of protein expression and gene status of human epidermal growth factor receptor (HER) family molecules in ameloblastomas.
Oikawa M; Miki Y; Shimizu Y; Kumamoto H
J Oral Pathol Med; 2013 May; 42(5):424-34. PubMed ID: 23278525
[TBL] [Abstract][Full Text] [Related]
18. Relationship between EGFR mutation and computed tomography characteristics of the lung in patients with lung adenocarcinoma.
Qiu X; Yuan H; Sima B
Thorac Cancer; 2019 Feb; 10(2):170-174. PubMed ID: 30516345
[TBL] [Abstract][Full Text] [Related]
19. Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma.
González-Alonso P; Chamizo C; Moreno V; Madoz-Gúrpide J; Carvajal N; Daoud L; Zazo S; Martín-Aparicio E; Cristóbal I; Rincón R; García-Foncillas J; Rojo F
Int J Mol Sci; 2015 Aug; 16(8):19447-57. PubMed ID: 26287187
[TBL] [Abstract][Full Text] [Related]
20. The involvement of EGFR, HER2 and HER3 in the basal cell carcinomas aggressiveness.
Florescu DE; Stepan AE; Mărgăritescu C; Ciurea RN; Stepan MD; Simionescu CE
Rom J Morphol Embryol; 2018; 59(2):479-484. PubMed ID: 30173251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
